Targets › MS4A1
28 programs from 22 companies in 535 trials: 296 Phase 2, 100 Phase 1, 92 Phase 3, 47 Phase 4; Oncology, Neurology, Immunology; next expected readout Nov 2026.
B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR. (UniProt, P11836)
Open in Phaseline: the race on MS4A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of California, San Francisco | Intravenous TXA Interleukin-23 inhibitor | ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4 | Phase 4 | Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke … | Dec 2026 |
| Novartis | Ofatumumab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 4 | Multiple Sclerosis; Relapsing-Remitting Multiple Sclerosis; Relapsing Multiple Sclerosis; Relapsing Multiple Sclerosis (RMS) … | Apr 2027 |
| Roche | Ocrelizumab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 4 | Relapsing Multiple Sclerosis; Progressive Multiple Sclerosis (PMS); Multiple Sclerosis; Multiple Sclerosis, Primary Progressive … | Sep 2027 |
| Roche | Ocrelizumab (rHuPH20) B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 4 | Multiple Sclerosis | Feb 2029 |
| AbbVie | Obinutuzumab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 3 | Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia (CLL) | Nov 2026 |
| Sandoz | Ocrelizumab (CYB704) B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 3 | Relapsing Multiple Sclerosis | Nov 2026 |
| TG Therapeutics | Ublituximab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 3 | Relapsing Multiple Sclerosis; Relapsing Multiple Sclerosis (RMS); Multiple Sclerosis; Myasthenia Gravis … | Jan 2027 |
| Roche | Glofitamab B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent | MS4A1, CD3E, CD3G, CD3D | Phase 3 | Lymphoma; Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma … | Jan 2027 |
| Biocad | divozilimab anti-CD20 monoclonal antibody | MS4A1 | Phase 3 | Neuromyelitis Optica Spectrum Disorders; Systemic Scleroderma | Feb 2027 |
| Celltrion | Ocrelizumab (P53) B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 3 | Relapsing-remitting Multiple Sclerosis | Feb 2027 |
| Acerta Pharma | Rituximab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 3 | Diffuse Large B-Cell Lymphoma | Feb 2027 |
| Roche | Mosunetuzumab T cell surface glycoprotein CD3 binding agent; B-lymphocyte antigen CD20 binding agent | CD3E, CD3G, CD3D, MS4A1 | Phase 3 | Non-Hodgkin Lymphoma; Relapsed or Refractory Follicular Lymphoma; Lupus; B-cell Non-Hodgkin Lymphoma … | Feb 2027 |
| Genmab | Epcoritamab B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent | MS4A1, CD3E, CD3G, CD3D | Phase 3 | Diffuse Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Follicular Lymphoma (FL); Non-Hodgkin Lymphoma … | Mar 2027 |
| Amgen | ABP 692 Anti-CD20 monoclonal antibody | MS4A1 | Phase 3 | Relapsing-remitting Multiple Sclerosis (RRMS) | Apr 2027 |
| Acerta Pharma | Obinutuzumab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 3 | Chronic Lymphocytic Leukemia | Apr 2027 |
| Roche | Obinutuzumab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 3 | Childhood Idiopathic Nephrotic Syndrome; Primary Membranous Nephropathy; Systemic Lupus Erythematosus; Lupus Nephritis … | Dec 2027 |
| Regeneron Pharmaceuticals | Odronextamab B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent | MS4A1, CD3E, CD3G, CD3D | Phase 3 | Follicular Lymphoma (FL); Diffuse Large B-cell Lymphoma (DLBCL); B-Cell Non-Hodgkin Lymphoma (B-NHL); Relapsed/Refractory Follicular Lymphoma … | Feb 2028 |
| Bristol-Myers Squibb | Rituximab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 3 | Follicular Lymphoma | Apr 2028 |
| Shanghai Henlius Biotech | Rituximab (HLX01) B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 2 | Membranous Nephropathy | Jan 2027 |
| BioRay Pharmaceutical | Rituximab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 2 | Primary Membranous Nephropathy | Mar 2027 |
| AstraZeneca | Rituximab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 2 | Mantle Cell Lymphoma (MCL); Diffuse Large B-Cell Lymphoma; Rheumatoid Arthritis (RA); ANCA Associated Vasculitis … | Oct 2028 |
| The Lymphoma Academic Research Organisation | CD20 Antibody Anti-CD20 monoclonal antibody | MS4A1 | Phase 2 | Mantle Cell Lymphoma | Mar 2030 |
| PolTREG | rituximab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 2 | Presymptomatic Diabetes Type 1 (Stage 1) | Dec 2032 |
| Byondis | Rituximab (BYON4228) B-lymphocyte antigen CD20 binding agent | MS4A1, SIRPA | Phase 1 | Lymphoma; Solid Tumor | Dec 2026 |
| ImmunityBio | Rituximab (CD19) B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 1 | Non-Hodgkin Lymphoma Refractory/ Relapsed | Oct 2027 |
| R-Pharm | Ocrelizumab (RPH-035) B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 1 | Multiple Sclerosis | Nov 2027 |
| Shanghai JMT-Bio | JMT601 anti-CD20 monoclonal antibody | MS4A1 | Phase 1 | B-cell Non Hodgkin Lymphoma | – |
| Biocad | Rituximab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 1 | Systemic Lupus Erthematosus | – |
Follicular Lymphoma (25) Mantle Cell Lymphoma (25) Chronic Lymphocytic Leukemia (25) Multiple Sclerosis (18) Lymphoma (15) Diffuse Large B-Cell Lymphoma (13) Marginal Zone Lymphoma (11) Large B-cell Lymphoma (9) Relapsing Multiple Sclerosis (8) Diffuse Large B Cell Lymphoma (8) Primary Central Nervous System Lymphoma (7) Recurrent Diffuse Large B-Cell Lymphoma (6)
mixed (16), protein or peptide (4), antibody (4), small molecule (3)
Roche (5) Biocad (2) Acerta Pharma (2) Regeneron Pharmaceuticals (1) Sandoz (1) Celltrion (1) TG Therapeutics (1) Genmab (1) Novartis (1) AbbVie (1) AstraZeneca (1) Bristol-Myers Squibb (1) University of California, San Francisco (1) ImmunityBio (1) Shanghai Henlius Biotech (1) Byondis (1) The Lymphoma Academic Research Organisation (1) BioRay Pharmaceutical (1) Amgen (1) PolTREG (1)
CD3E (4) CD3G (4) CD3D (4) ADRB2 (1) AGTR1 (1) IL12B (1) IL23A (1) PDCD1 (1) NR3C1 (1) HTR2A (1) MAP2K1 (1) MAP2K2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.